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LETTER
Reply to Scahill: Behavioral outcome measures
in autism
We thank Lawrence Scahill for his comments
(1) on our use of outcome measures in our
clinical trial of sulforaphane in autism spec-
trum disorder (ASD) (2). Scahill identifies
some differences in our use of these scales
from how they have been used in some other
trials, but we believe that our interpretations
of the trial results are accurate. We chose the
Social Responsiveness Scale (SRS) because we
were especially interested in assessing socia-
bility in autism, which is a cardinal feature of
ASD and is frequently reported to improve
during fever. To our knowledge, this is the
first clinical trial in ASD in which the SRS
was a primary outcome measure and has also
shown positive results. The Aberrant Behav-
ior Checklist (ABC) and Clinical Global Im-
pression Improvement (CGI-I) are more con-
ventional measures in ASD clinical trials.
The baseline ABC and its subscale scores
are reported in table S1 of the original article
(2). We agree that the differences between
sulforaphane and placebo ABC subscale
scores are modest. We reported the total
ABC (and SRS) scores because the study
was powered on them. A statistical analysis
on the ABC subscale scores did reveal that,
although modest, the differences in change
from baseline were significant in the ABC
irritability and lethargy subscales (figure 3
from ref. 2).
We used a version of CGI-I [The Ohio
Autism Clinical Impressions Scale (OACIS)]
that has been specifically adapted for use in
autism spectrum disorders by The Ohio State
University Research Unit on Pediatric Psy-
chopharmacology, which, in addition to
considering the overall severity or improve-
ment of autism symptoms, also considers
nine different subdomains of ASD symp-
toms. Thus, we believe use of the OACIS
provided us a more precise assessment of
severity (and improvement) of our study
participants. The general level of autism
was improved in only three domains of
autistic behavior.
The discontinuation phase was indeed
placebo controlled, and the trial remained
double blind until all subjects had completed
the study. The sample size in this phase was
reduced due to lower rates of follow-up for
the final study visit.
We respectfully point out that the three
expert reviewers (identified in the paper) and
the accepting editor for PNAS found no
problems with our method of assessment of
behavior in ASD.
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